Lv1
98 积分 2022-01-13 加入
Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients
22天前
已完结
Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study
2个月前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
2个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2个月前
已完结
Online Risk Scores for Pre- and Postoperative Prediction of Early Recurrence in Hepatocellular Carcinoma Patients Undergoing Conversion Liver Resection After Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors Therapy
8个月前
已关闭
皖公网安备34019202002308
